Malignant mixed tumor
Also known as: Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Malignant mixed tumor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Malignant mixed tumor (also termed Metastasis or Metastases) is an ICD-10-CM indexed diagnosis (C44.99) within Cancer, Oncology & Supportive Care.
- 2 Real-world patient consensus: Synonyms for Malignant mixed tumor (C44.99): Metastasis, Metastases, Metastatic (Cancer & Oncology).
- 3 Typical cash cost range: Clinicians assessing Malignant mixed tumor focus on somatic oncogenic driver in Malignant mixed tumor (C44.99: mutations) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Malignant mixed tumor monitoring tracks Complete Blood Count in Malignant mixed tumor (C44.99: (ANC, Hemoglobin, Platelets)) toward Safe hematologic reserve (C44.99).
Ask our AI Specialists anything about Malignant mixed tumor
What Is Malignant mixed tumor?
Malignant mixed tumor (also termed Metastasis or Metastases) is an ICD-10-CM indexed diagnosis (C44.99) within Cancer, Oncology & Supportive Care. Clinical evaluation centers on tissue biopsy with in Malignant mixed tumor (C44.99: histopathology) alongside serial Complete Blood Count in Malignant mixed tumor (C44.99: (ANC, Hemoglobin, Platelets)) tracking (Safe hematologic reserve (C44.99)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
In Malignant mixed tumor (C44.99), physiological disruption stems from somatic oncogenic driver in Malignant mixed tumor (C44.99: mutations), informing Cancer, Oncology & Supportive Care protocols that track Comprehensive Metabolic & in Malignant mixed tumor (C44.99: Organ Function Panel) (Preserved renal/hepatic clearance (C44.99)).
Common Symptoms & Clinical Signs
- • Presentation of Malignant mixed tumor (C44.99): abnormality detected early in Malignant mixed tumor (C44.99: on age-appropriate screening)
- • Secondary Malignant mixed tumor clinical sign: persistent painless lump, in Malignant mixed tumor (C44.99: non-healing ulcer/mole change,)
- • Symptom flares in Malignant mixed tumor correlating with Complete Blood Count in Malignant mixed tumor (C44.99: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C44.99)
- • Functional cancer & oncology impact requiring tissue biopsy with in Malignant mixed tumor (C44.99: histopathology) evaluation (C44.99)
Malignant mixed tumor Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C44.99 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Complete Blood Count in Malignant mixed tumor (C44.99: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C44.99) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Malignant mixed tumor (C44.99: Organ Function Panel) | Preserved renal/hepatic clearance (C44.99) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Malignant mixed tumor (C44.99: Genomic Staging) | Guideline-concordant surveillance (C44.99) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Malignant mixed tumor
Treatment selection for Malignant mixed tumor depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Malignant mixed tumor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of low-dose tamoxifen on benign gynecological and breast conditions in a Compared with data on standard-dose tamoxifen, rates of benign events were lower. Journal of the National Cancer Institute • 2026-06-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40880294 ↗ |
| Can This Approach Help? Inside the Latest Research on Influence of different photobiomodulation protocols on the prevention of Protocols R or IR proved to be inferior to the R + IR laser photobiomodulation protocol. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2025-07-14 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 40658227 ↗ |
| Can This Approach Help? Inside the Latest Research on Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate No new safety signals were observed across subgroups. European urology oncology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41027802 ↗ |
| Cost-effectiveness analysis of nivolumab vs. Placebo: Which Works Better for Relapsed malignant mesothelioma? From the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma. International journal of clinical pharmacy • 2024-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37991664 ↗ |
| Can This Approach Help? Inside the Latest Research on Prognostic value of patient-reported outcomes in advanced or metastatic melanoma PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. European journal of cancer (Oxford, England : 1990) • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39520835 ↗ |
Malignant mixed tumor Patient Community & “People Like Me” Threads
Filter Malignant mixed tumor community threads and patient logs by age, biological sex, dosage, and treatment duration.